FOSTER CITY, Calif. — November 18, 2025 — Leads & Copy — Apollomics Inc. (Nasdaq: APLM) has appointed Dr. Ya-Chi (Claudia) Huang to its board of directors and Audit and Nominating and Corporate Governance Committees.
The appointment, which was effective November 16, 2025, fills the vacancy created by the resignation of Mr. Po-Jen Hsueh, who stepped down from the board on November 16, 2025. His resignation was not due to any disagreement with the company.
Dr. Huang will also take Mr. Hsueh’s place on the company’s Audit Committee and Nominating and Corporate Governance Committee. Following these changes, the company’s board is comprised of seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang.
Independent directors include Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang.
Dr. Huang brings extensive experience in biotechnology investment, corporate governance, and research and development within Taiwan’s biopharmaceutical industry.
Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics.
Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond’s portfolio companies. She participated in Diamond Biofund’s IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong and contributed to a significant increase in Fubon Securities’ investment banking profits.
Dr. Huang’s scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award.
Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University.
Apollomics Inc. is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.
Peter Lin, Chief Financial Officer Apollomics, Inc. Phone: 1-650-209-4055 Email: peter.lin@apollomicsinc.com
Source: Apollomics Inc.
